Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.

Original title: “Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion”

The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus.

Original title: “Sanofi breaks ground on insulin plant after securing German government support”

Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.

Original title: “Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues”

The global clinical trials market was valued at an estimated USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, expanding at a compound annual growth rate of 7.7% from 2026 to 2033. According to the report, market growth is supported by the rising prevalence of chronic and rare diseases, increasing demand for innovative therapies... The global clinical trials market was valued at an estimated USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, expanding at a compound annual growth rate of 7.7% from 2026 to 2033. According to the report, market growth is supported by the rising prevalence of chronic and rare diseases, increasing demand for innovative therapies, advances in biotechnology and precision medicine, and higher research and development investment from pharmaceutical and biopharmaceutical companies. New Report puts the global market at $89bn in 2025, with chronic and rare disease, precision medicine and outsourcing to contract researchers driving... It evaluates current clinical trials industry trends and market opportunities across phase, study design, indication, indication by study design, service, sponsor, and region. Phase: Phase I, Phase II, Phase III, and Phase IV. Study design: Interventional trials, observational trials, and expanded access trials. Indication: Autoimmune/inflammation, pain management, oncology, CNS conditions, diabetes, obesity, cardiovascular diseases, and other therapeutic areas. The indication-by-study-design analysis assesses interventional, observational, and expanded access trials across autoimmune/inflammation, pain management, oncology, CNS conditions, diabetes, obesity, cardiovascular diseases, and additional indications. This structure enables stakeholders to compare revenue potential and clinical research activity across major therapeutic and study categories.

Original title: “Global Clinical Trials Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 158.4 Billion at 7.7% CAGR as Decentralized Trials and R&D Outsourcing Accelerate”

Saudi Arabia’s biotech strategy now has named partners, sites and capital behind it.

Original title: “From strategy to scale: How Saudi Arabia is building a biotech ecosystem”

Discover which CMC activities can move forward early, and which decisions need to remain flexible.

Original title: “How early should you engage a CDMO?”

High-quality cytokines for organoid growth, differentiation, and expansion

Original title: “From cells to organoids: Cytokines that shape 3D culture”

As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities.

Original title: “More arms, more questions: The new challenge in multispecific drug design”